Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 + MK-8742 in chronic hepatitis C with advanced cirrhosis and Child-Pugh B hepatic insufficiency
2014-000672-25Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of grazoprevir and verubecestat in hepatitis C virus infection, sponsored by Merck & Co. Primary endpoints: SVR12 in Child-Pugh B subjects treated with the dose of MK-5172 used in Part C and Mean improvement in MELD score from baseline to follow-up week 12. Started Nov 2014; status: terminated.
02
Drugs
grazoprevirverubecestat
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-000672-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000672-25.